The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Open accessPublished version of a preprint
Abstract
Tumor protein p53 (TP53) is the most frequently mutated gene in cancer 1,2. In patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease 3,4, rapid transformation to acute myeloid leukemia (AML)5, resistance to conventional therapies 6-8 and dismal outcomes 9. Consistent with the tumor-suppressive role of TP53, patients harbor both mono- and biallelic mutations 10. However, the biological and clinical implications of TP53 allelic state have not been fully investigated in MDS or any other cancer type. We analyzed 3,324 patients with MDS for TP53 mutations and allelic imbalances and delineated two subsets of patients with distinct phenotypes and outcomes. One-third of TP53-mutated patients had monoallelic mutations whereas two-thirds had multiple hits (multi-hit) consistent with biallelic targeting. Established associations with complex karyotype, few co-occurring mutations, high-risk presentation and poor outcomes were specific to multi-hit patients only. TP53 multi-hit state predicted risk of death and leukemic transformation independently of the Revised International Prognostic Scoring System (IPSS-R)11. Surprisingly, monoallelic patients did not differ from TP53 wild-type patients in outcomes and response to therapy. This study shows that consideration of TP53 allelic state is critical for diagnostic and prognostic precision in MDS as well as in future correlative studies of treatment response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment outcomes for patients with TP53 mutations are poor with available therapies.8-12”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The TP53 mutation burden (ie, high variant allele frequency [VAF], concurrent complex karyotype, and/or multihit state) is integrally linked to inferior survival with median OS of 6-8 months.8-10,12”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, remissions in TP53-mutant patients are brief with a median overall survival (OS) ranging from 5 to 12 months,8,9,12,13,15-17”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53 gene mutations (mTP53) represent a distinct molecular cohort with poor outcomes.”
From Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53 gene mutations (mTP53) are found in up to 20% of myelodysplastic syndromes/neoplasms (MDS) or acute myeloid leukemia (AML) pts and 30%–40% of therapy‐related (TR) MDS/AML cases”
From Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML (2025) · cites this paper as [3]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Specifically, mTP53 patients with a high variant allele frequency (VAF; i.e., >20%–23%), biallelic state, and/or complex karyotype (CK) have particularly poor risk.”
From Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML (2025) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Despite the known dominant negative and/or gain of function effect of certain TP53 mutations28,42, loss of the TP53-WT allele, a genetic event associated with a particularly dismal prognosis2, confers an additional fitness advantage to TP53-sAML LSCs.”
From Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution (2023) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
The mutational constraint spectrum quantified from variation in 141,456 humans
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2308-7 · Cited by 9,434
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965
COSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Self-citation
Cited by
Sorted by citations
Items 101–200 of 648
Komrokji, R. S., Lanino, L., Ball, S., Bewersdorf, J. P., Marchetti, M., Maggioni, G., Travaglino, E., Ali, N. H. A., Fenaux, P., Platzbecker, U., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00251-5 · Cited by 31
Self-citationPatel, S. A., Lloyd, M. R., Černý, J., Shi, Q., Simin, K. J., Ediriwickrema, A., Hutchinson, L., Miron, P. M., Higgins, A. W., Ramanathan, M., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1957869 · Cited by 31
Lee, W., Lin, C., Tsai, C., Tien, F., Lo, M., Tseng, M., Kuo, Y., Yu, S., Liu, M.-C., Yuan, C., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01031-9 · Cited by 30
Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia
Zhang, Z., Huang, J., Zhang, Z., Shen, H., Tang, X., Wu, D., Bao, X., Xu, G., & Chen, S. (2024) · Biomarker Research · doi:10.1186/s40364-024-00600-1 · Cited by 30
Montoro, M. J., Palomo, L., Haferlach, C., Acha, P., Chan, O., Navarro, V., Kubota, Y., Schulz, F. I., Meggendorfer, M., Briski, R. E., et al. (2024) · Blood · doi:10.1182/blood.2024023840 · Cited by 31
Self-citationTP53 Mutations in Myeloproliferative Neoplasms: Context‐Dependent Evaluation of Prognostic Relevance
Tefferi, A., Abdelmagid, M. G., Loscocco, G. G., Fathima, S., Begna, K. H., Al‐Kali, A., Foran, J. M., Palmer, J. M., Badar, T., Patnaik, M. M., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.27609 · Cited by 30
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Marmouset, V., Decroocq, J., Garciaz, S., Étienne, G., Belhabri, A., Bertoli, S., Gastaud, L., Simand, C., Chantepie, S., Uzunov, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1622 · Cited by 30
Self-citationZeidan, A. M., Bewersdorf, J. P., Buckstein, R. J., Sekeres, M. A., Steensma, D. P., Platzbecker, U., Loghavi, S., Boultwood, J., Bejar, R. L., Bennett, J. M., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01724-9 · Cited by 32
Self-citationTransplant for TP53-mutated MDS and AML: because we can or because we should?
Versluis, J., & Lindsley, R. C. (2022) · Hematology · doi:10.1182/hematology.2022000354 · Cited by 30
Stengel, A., Haferlach, T., Baer, C. R., Hütter, S., Meggendorfer, M., Kern, W., & Haferlach, C. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009100 · Cited by 30
What is new in acute myeloid leukemia classification?
Park, H. S. (2024) · Blood Research · doi:10.1007/s44313-024-00016-8 · Cited by 29
Gurnari, C., Robin, M., Adès, L., Aljurf, M. D., Almeida, A. M., Duarte, F. B., Bernard, E., Cutler, C. S., Porta, M. G. D., de Witte, T. M., et al. (2025) · Blood · doi:10.1182/blood.2024025131 · Cited by 29
Self-citationTransient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin
Marcellino, B. K., Farnoud, N. R., Cassinat, B., Lü, M., Verger, E., McGovern, E. M., Patel, M. A., Medina-Martinez, J. S., Levine, M. F., Ossa, J. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002379 · Cited by 31
Self-citationDeciphering the Therapeutic Resistance in Acute Myeloid Leukemia
Gurnari, C., Pagliuca, S., & Visconte, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228505 · Cited by 31
The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia
Bănescu, C. V., Tripon, F., & Muntean, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065734 · Cited by 29
Nannya, Y., Tobiasson, M., Sato, S., Bernard, E., Ohtake, S., Takeda, J., Creignou, M., Zhao, L., Kusakabe, M., Shibata, Y., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009564 · Cited by 29
Self-citationKwok, M., Agathanggelou, A., & Stanković, T. (2024) · Blood · doi:10.1182/blood.2023019963 · Cited by 30
Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments
Granowicz, E. M., & Jonas, B. A. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s265637 · Cited by 31
Amplified EPOR / JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
Takeda, J., Yoshida, K., Nakagawa, M. M., Nannya, Y., Yoda, A., Saiki, R., Ochi, Y., Zhao, L., Okuda, R., Qi, X., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0192 · Cited by 28
Self-citationGarcía-Gisbert, N., Arenillas, L., Roman-Bravo, D., Rodríguez‐Sevilla, J. J., Fernández‐Rodríguez, C., Garcia-Ávila, S., Vélez, P., Gibert, J., Fernández‐Ibarrondo, L., Salar, A., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01733-8 · Cited by 28
Have we reached a molecular era in myelodysplastic syndromes?
Voso, M. T., & Gurnari, C. (2021) · Hematology · doi:10.1182/hematology.2021000276 · Cited by 27
Self-citationKaisrlikova, M., Veselá, J., Kundrát, D., Votavová, H., Merkerová, M. D., Krejčík, Z., Divoký, V., Jedlička, M., Frič, J., Kléma, J., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01584-3 · Cited by 27
Gondek, L. P., Sheehan, V., & Fitzhugh, C. D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113160 · Cited by 27
Genetic landscape of chronic myeloid leukemia
Ochi, Y. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03510-w · Cited by 27
Gagelmann, N., Badbaran, A., Salit, R. B., Schroeder, T. A., Gurnari, C., Pagliuca, S., Panagiota, V., Rautenberg, C., Cassinat, B., Thol, F. R., et al. (2023) · Blood · doi:10.1182/blood.2023019630 · Cited by 27
Self-citationDuong, V. H., Ruppert, A. S., Mims, A. S., Borate, U., Stein, E. M., Baer, M. R., Stock, W., Kovacsovics, T. J., Blum, W. G., Arellano, M. L., et al. (2023) · Cancer · doi:10.1002/cncr.34780 · Cited by 27
Epidemiology and Pathogenesis of Myelodysplastic Syndrome
Rotter, L. K., Shimony, S. O., Ling, K., Chen, E., Shallis, R. M., Zeidan, A. M., & Stahl, M. F. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000665 · Cited by 27
Bataller, Á., Bravo, G. M., Bazinet, A., Alvarado, Y., Chien, K. S., Venugopal, S., Ishizawa, J., Hammond, D. E., Swaminathan, M., Sasaki, K., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00367-8 · Cited by 25
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 29
British Society for Haematology guidelines for the management of adult myelodysplastic syndromes
Killick, S. B., Ingram, W. A., Culligan, D. J., Enright, H., Kell, J., Payne, E. M., Krishnamurthy, P., Kulasekararaj, A. G., Raghavan, M., Stanworth, S. J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17612 · Cited by 25
Self-citationGarcia‐Manero, G. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00265-4 · Cited by 26
Updates in molecular genetics of acute myeloid leukemia
Kurzer, J. H., & Weinberg, O. K. (2023) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2023.04.002 · Cited by 28
p53 biology and reactivation for improved therapy in MDS and AML
Zawacka‐Pankau, J. (2024) · Biomarker Research · doi:10.1186/s40364-024-00579-9 · Cited by 25
Unravelling the Epigenome of Myelodysplastic Syndrome: Diagnosis, Prognosis, and Response to Therapy
Bond, D. R., Lee, H. J., & Enjeti, A. K. (2020) · Cancers · doi:10.3390/cancers12113128 · Cited by 26
Kanagal‐Shamanna, R., Puiggros, A., Granada, I., Raca, G., Rack, K. A., Mallo, M., Dewaele, B., Smith, A. C., Akkari, Y. M. N., Levy, B., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.27688 · Cited by 25
Self-citationGenetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
Palomo, L., Acha, P., & Solé, F. G. (2021) · Cancers · doi:10.3390/cancers13092120 · Cited by 24
Self-citationVenetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes
Shimony, S. O., Stone, R. M., & Stahl, M. F. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000698 · Cited by 24
Fitzpatrick, M. J., Boiocchi, L., Fathi, A. T., Brunner, A. M., Hasserjian, R. P., & Nardi, V. (2022) · Histopathology · doi:10.1111/his.14726 · Cited by 24
Self-citationBellizzi, A. M. (2023) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000001144 · Cited by 24
Patel, S. A., Černý, J., Gerber, W. K., Ramanathan, M., Ediriwickrema, A., Tanenbaum, B., Hutchinson, L., Meng, X., Flahive, J., BARTON, B. A., et al. (2023) · eJHaem · doi:10.1002/jha2.791 · Cited by 24
Awada, H. K., Thapa, B., & Visconte, V. (2020) · Cells · doi:10.3390/cells9112512 · Cited by 26
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations
Shah, M. V., Hung, K., Baranwal, A., Kutyna, M. M., Al-Kali, A., Toop, C., Greipp, P., Brown, A., Shah, S., Khanna, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015238 · Cited by 23
The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?
Cook, M. R., Karp, J. E., & Lai, C. (2021) · eJHaem · doi:10.1002/jha2.317 · Cited by 26
Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation
Rodríguez‐Sevilla, J. J., Ademà, V., Garcia‐Manero, G., & Colla, S. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100940 · Cited by 23
Convergent somatic evolution commences in utero in a germline ribosomopathy
Machado, H. E., Øbro, N. F., Williams, N., Tan, S., Boukerrou, A. Z., Davies, M., Belmonte, M., Mitchell, E., Baxter, E. J., Mende, N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40896-5 · Cited by 25
Halik, A., Tilgner, M., Silva, P., Estrada, N., Altwasser, R., Jahn, E., Heuser, M., Hou, H., Pratcorona, M., Hills, R. K., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01590-1 · Cited by 25
Self-citationGagelmann, N., & Kröger, N. M. (2025) · American Journal of Hematology · doi:10.1002/ajh.27660 · Cited by 24
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation
Uryu, H., Saeki, K., Haeno, H., Kapadia, C. D., Furudate, K., Nangalia, J., Chapman, M. S., Zhang, L., Padilla, J., Zhao, L., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02235-w · Cited by 26
TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
Niparuck, P., Police, P., Noikongdee, P., Siriputtanapong, K., Limsuwanachot, N., Rerkamnuaychoke, B., Chuncharunee, S., & Siriboonpiputtana, T. (2021) · Diagnostic Pathology · doi:10.1186/s13000-021-01162-8 · Cited by 22
The genetics of myelodysplastic syndromes and the opportunities for tailored treatments
Kontandreopoulou, C., Kalopisis, K., Viniou, N., & Diamantopoulos, P. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.989483 · Cited by 23
Feng, J., Lan, Y., Liu, F., Yuan, Y., Ge, J., Wei, S., Luo, H., Li, J., Luo, T., & Bian, X. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00465-x · Cited by 22
Combined landscape of single-nucleotide variants and copy-number alterations in clonal hematopoiesisPreprint
Saiki, R., Momozawa, Y., Nannya, Y., Nakagawa, M. M., Ochi, Y., Yoshizato, T., Terao, C., Kuroda, Y., Shiraishi, Y., Chiba, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.05.433727 · Cited by 22
Self-citationClonal hematopoiesis and bone marrow failure syndromes
Paşca, S., & Gondek, L. P. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101273 · Cited by 21
Zampini, M., Riva, E., Lanino, L., Sauta, E., Reis, R. A. D., Ejarque, R. A., Maggioni, G., Termanini, A., Merlotti, A., Campagna, A., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02394 · Cited by 21
Self-citationA clinical guide to TP53 mutations in myeloid neoplasms
Urrutia, S., Wong, T. N., & Link, D. C. (2025) · Blood · doi:10.1182/blood.2025029691 · Cited by 22
Becker, H., Pfeifer, D., Ihorst, G., Pantić, M., Wehrle, J., Rüter, B. H., Bullinger, L., Hackanson, B. W., Germing, U., Kuendgen, A., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04082-7 · Cited by 21
Self-citationSill, H., Zebisch, A., & Haase, D. T. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2272 · Cited by 23
Self-citationFrom Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression
Gurnari, C., Fabiani, E., Falconi, G., Travaglini, S., Ottone, T., Cristiano, A., & Voso, M. T. (2021) · Biology · doi:10.3390/biology10020128 · Cited by 22
Self-citationTP53 in Myelodysplastic Syndromes
Jiang, Y., Gao, S., Soubise, B., Douet‐Guilbert, N., Liu, Z., & Troadec, M. (2021) · Cancers · doi:10.3390/cancers13215392 · Cited by 22
Sallman, D. A., Komrokji, R. S., Dezern, A. E., Sebert, M., Garcia‐Manero, G., Rahmé, R., Winer, E. S., Lehmann‐Che, J., Roboz, G. J., Madelaine, I., et al. (2025) · HemaSphere · doi:10.1002/hem3.70164 · Cited by 26
Self-citationSingle-cell methods in myeloproliferative neoplasms: old questions, new technologies
O’Sullivan, J., Mead, A. J., & Psaila, B. (2022) · Blood · doi:10.1182/blood.2021014668 · Cited by 24
Zhong, F., Yao, F., Liu, J., Zhang, H., Zhang, J., Zhang, N., Jin, L., Li, S., Li, M., Jiang, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.888570 · Cited by 20
Bewersdorf, J. P., Xie, Z., Bejar, R. L., Borate, U., Boultwood, J., Brunner, A. M., Buckstein, R. J., Carraway, H. E., Churpek, J. E., Daver, N. G., et al. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101072 · Cited by 22
Self-citationPereira, M. P., Herrity, E., & Kim, D. D. H. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05462-5 · Cited by 20
SF3B1 mutant myelodysplastic syndrome: Recent advances
Pellagatti, A., & Boultwood, J. (2020) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100776 · Cited by 20
Self-citationCHIP: is clonal hematopoiesis a surrogate for aging and other disease?
Gondek, L. P. (2021) · Hematology · doi:10.1182/hematology.2021000270 · Cited by 21
Myelodysplasia Syndrome, Clonal Hematopoiesis and Cardiovascular Disease
Veiga, C. B., Lawrence, E., Murphy, A. J., Herold, M. J., & Dragoljevic, D. (2021) · Cancers · doi:10.3390/cancers13081968 · Cited by 20
Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
Cluzeau, T., Loschi, M. L., Fenaux, P., Komrokji, R. S., & Sallman, D. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810105 · Cited by 20
Self-citationTsai, H. K., Gibson, C. J., Murdock, H. M., Davineni, P. K., Harris, M. H., Wang, E. S., Gondek, L. P., Kim, A. S., Nardi, V., & Lindsley, R. C. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007613 · Cited by 19
TP53 in AML and MDS: The new (old) kid on the block
Marks, J. A., Wang, X., Fenu, E. M., Bagg, A., & Lai, C. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101055 · Cited by 20
Lee, C., Kim, H. N., Kwon, J. A., Yoon, S., Jeon, M. J., Yu, E. S., Kim, D. S., Choi, C. W., & Yoon, J. H. (2023) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.43.5.503 · Cited by 19
Orgueira, A. M., Pérez‐Encinas, M., Varela, N. A. D., Mora, E., Díaz‐Beyá, M., Montoro, M. J., Pomares, H., Ramos, F., Tormo, M., Jerez, A., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000961 · Cited by 19
Cytogenetics and genomics of acute myeloid leukemia
Snaith, O., Poveda-Rogers, C., Laczko, D. I., Yang, G., & Morrissette, J. J. D. (2023) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2023.101533 · Cited by 23
Nachtkamp, K., Strupp, C., Vukelja, M., Kasprzak, A., Haase, D. T., Ganster, C., Hildebrandt, B., Betz, B., Giagounidis, A. A. N., Aul, C., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02157-2 · Cited by 19
Self-citationDiagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classifications
Hart, S. A., Lee, L. A., Seegmiller, A. C., & Mason, E. F. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014140 · Cited by 19
Myelodysplastic syndromes: new methods of diagnosis, prognostication, and treatment
Nachtkamp, K., Kobbe, G., Gattermann, N., & Germing, U. (2023) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2023.0005 · Cited by 19
Self-citationClinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults
Harris, E. J., Karaoğlu, D. A., SUKHANOVA, M. J., Abaza, Y., Karantanos, T., Eisfeld, A., Anderson, C. E., Lin, C., Vanegas, Y. A. M., Badar, T., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01350-5 · Cited by 18
Bewersdorf, J. P., & Zeidan, A. M. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101245 · Cited by 18
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms
Kaur, A., Rojek, A. E., Symes, E., Nawas, M. T., Patel, A. A., Patel, J. L., Sojitra, P., Aqil, B., SUKHANOVA, M. J., McNerney, M. E., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01077-9 · Cited by 18
Maimaiti, A., Wang, X., Pei, Y., Nuermaimaiti, N., Tuersunniyazi, A., Abula, Y., Feng, Z., Jiang, L., Shi, X., & Kasimu, M. (2021) · Aging · doi:10.18632/aging.203079 · Cited by 18
Kanagal‐Shamanna, R., Orazi, A., Hasserjian, R. P., Arber, D. A., Reichard, K. K., Hsi, E. D., Bagg, A., Rogers, H. J., Geyer, J. T., Darbaniyan, F., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00961-0 · Cited by 17
Self-citationProgress toward Better Treatment of Therapy-Related AML
Kotsiafti, A., Giannakas, K., Christoforou, P., & Liapis, K. (2023) · Cancers · doi:10.3390/cancers15061658 · Cited by 18
Gurney, M. E., Mangaonkar, A. A., Lasho, T. L., Finke, C. M., Al‐Kali, A., Gangat, N., Shah, M. V., Alkhateeb, H. B., Tefferi, A., Sallman, D. A., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01964-3 · Cited by 17
Murphy, T., Mason, J. M., Leber, B. F., Bray, M. R., Chan, S. M., Gupta, V. K., Khalaf, D., Maze, D. C., McNamara, C. J., Schimmer, A. D., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02110-9 · Cited by 17
Jambhekar, A., Ackerman, E. E., Alpay, B. A., Lahav, G., & Lovitch, S. B. (2024) · Blood Neoplasia · doi:10.1016/j.bneo.2024.100004 · Cited by 17
Asimomitis, G., Deslauriers, A. G., Kotini, A. G., Bernard, E., Esposito, D., Olszewska, M., Spyrou, N., Ossa, J. A., Blanco, T. M., Koche, R. P., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006325 · Cited by 18
Self-citationRasmussen, B. E. H., Göhring, G., Bernard, E., Nilsson, L., Tobiasson, M., Jädersten, M., Garelius, H. G., Dybedal, I., Grønbæk, K., Ejerblad, E., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01537-w · Cited by 18
Self-citationZhao, D., Eladl, E., Zarif, M., Capo‐Chichi, J., Schuh, A. C., Atenafu, E. G., Minden, M. D., & Chang, H. (2022) · Cancer Medicine · doi:10.1002/cam4.5421 · Cited by 17
Zeidan, A. M., Bewersdorf, J. P., Gray, V. E., Shallis, R. M., Thompson, E. G., Menezes, D. L. D., Rose, S., Boss, I. W., Halene, S., Haferlach, T., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01766-z · Cited by 17
Akkari, Y. M. N., Baughn, L. B., Kim, A., Karaca, E., Raca, G., Shao, L., & Mikhail, F. M. (2024) · Genetics in Medicine · doi:10.1016/j.gim.2023.101054 · Cited by 16
Baumann, A., Buribayev, Z., Wolkenhauer, O., Salybekov, A. A., & Wolfien, M. (2025) · Epigenomes · doi:10.3390/epigenomes9010005 · Cited by 18
Awada, H., Gurnari, C., Durmaz, A., Awada, H. K., Pagliuca, S., & Visconte, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052802 · Cited by 16
Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms
Shah, M. V., Chhetri, R., Dholakia, R., Kok, C. H., Gangat, N., Alkhateeb, H. B., Al‐Kali, A., Patnaik, M. M., Baranwal, A., Greipp, P. T., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26589 · Cited by 16
Updates on the Management of Acute Myeloid Leukemia
Huerga-Domínguez, S., Villar, S., Prósper, F., & Piérola, A. A. (2022) · Cancers · doi:10.3390/cancers14194756 · Cited by 16
Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia
Ambinder, A. J., & Dezern, A. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1033534 · Cited by 16
Jann, J.-C., Hergott, C. A., Winkler, M., Liu, Y., Braun, B., Charles, A. L., Copson, K. M., Barua, S., Meggendorfer, M., Nadarajah, N., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02347-y · Cited by 16
Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
Kasprzak, A., Nachtkamp, K., Gattermann, N., & Germing, U. (2022) · Cancers · doi:10.3390/cancers14081941 · Cited by 16
Self-citationCytotoxic Cyclotides from Anchietea pyrifolia, a South American Plant Species
Bobey, A. F., Pinto, M. E. F., de Almeida, L. C., de Souza, B. M., Días, N. B., de Paula‐Souza, J., Cilli, E. M., Lopes, N. P., Costa-Lotufo, L. V., Palma, M. S., et al. (2022) · Journal of Natural Products · doi:10.1021/acs.jnatprod.1c01129 · Cited by 16
Shallis, R. M., Daver, N. G., Altman, J. K., Hasserjian, R. P., Kantarjian, H. M., Platzbecker, U., Santini, V., Wei, A. H., Sallman, D. A., & Zeidan, A. M. (2022) · Cancer · doi:10.1002/cncr.34535 · Cited by 16
Self-citationShah, M. V., Hung, K., Baranwal, A., Wechalekar, G., Al‐Kali, A., Toop, C. R., Greipp, P. T., Kutyna, M., Matin, A., Ładoń, D., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01290-0 · Cited by 15
Metadata
- Authors
- Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., Levine, M. F., Arango, J. E., Zhou, Y., Solé, F., Cargo, C. A., Haase, D., Creignou, M., Germing, U., Zhang, Y., Gundem, G., Sarian, A., van de Loosdrecht, A. A., Jädersten, M., Tobiasson, M., Kosmider, O., Follo, M. Y., Thol, F., Pinheiro, R. F., Santini, V., Kotsianidis, I., Boultwood, J., Santos, F. P. S., Schanz, J., Kasahara, S., Ishikawa, T., Tsurumi, H., Takaori-Kondo, A., Kiguchi, T., Polprasert, C., Bennett, J. M., Klimek, V. M., Savona, M. R., Belickova, M., Ganster, C., Palomo, L., Sanz, G., Ades, L., Della Porta, M. G., Elias, H. K., Smith, A. G., Werner, Y., Patel, M., Viale, A., Vanness, K., Neuberg, D. S., Stevenson, K. E., Menghrajani, K., Bolton, K. L., Fenaux, P., Pellagatti, A., Platzbecker, U., Heuser, M., Valent, P., Chiba, S., Miyazaki, Y., Finelli, C., Voso, M. T., Shih, L.-Y., Fontenay, M., Jansen, J. H., Cervera, J., Atsuta, Y., Gattermann, N., Ebert, B. L., Bejar, R., Greenberg, P. L., Cazzola, M., Hellström-Lindberg, E., Ogawa, S., & Papaemmanuil, E.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Kyoto University (JP)
- Massachusetts General Hospital (US)
- University of Pavia (IT)
- Josep Carreras Leukaemia Research Institute (ES)
- St James's University Hospital (GB)
- Universitätsmedizin Göttingen (DE)
- Karolinska University Hospital (SE)
- Heinrich Heine University Düsseldorf (DE)
- Université Paris Cité (FR)
- University of Bologna (IT)
- Medizinische Hochschule Hannover (DE)
- Universidade Federal do Ceará (BR)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- University of Oxford (GB)
- Gifu Municipal Hospital (JP)
- Kobe City Medical Center General Hospital (JP)
- Gifu University (JP)
- Chugoku Central Hospital (JP)
- Chulalongkorn University (TH)
- University of Rochester Medicine (US)
- Vanderbilt University (US)
- Instituto de Salud Carlos III (ES)
- University of York (GB)
- Dana-Farber Cancer Institute (US)
- Hôpital Saint-Louis (FR)
- Leipzig University (DE)
- Ludwig Boltzmann Institute for Hematology and Oncology (AT)
- University of Tsukuba (JP)
- Nagasaki University (JP)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- University of Rome Tor Vergata (IT)
- Chang Gung University (TW)
- Radboud University Medical Center (NL)
- Hospital Universitari i Politècnic La Fe (ES)
- The Japanese Data Center for Hematopoietic Cell Transplantation (JP)
- Howard Hughes Medical Institute (US)
- Moores Cancer Center (US)
- Stanford Cancer Institute (US)
- Corresponding author
- Papaemmanuil, Elli
- ORCID
- Bernard, Elsa
- Nannya, Yasuhito
- Hasserjian, Robert P.
- Devlin, Sean M.
- Tuechler, Heinz
- Medina-Martinez, Juan S.
- Yoshizato, Tetsuichi
- Saiki, Ryunosuke
- Malcovati, Luca
- Levine, Max F.
- Solé, Francesc
- Cargo, Catherine A.
- Creignou, Maria
- Germing, Ulrich
- Zhang, Yanming
- Gundem, Gunes
- Jädersten, Martin
- Tobiasson, Magnus
- Kosmider, Olivier
- Follo, Matilde Y.
- Thol, Felicitas
- Pinheiro, Ronald F.
- Santini, Valeria
- Boultwood, Jacqueline
- Schanz, Julie
- Kasahara, Senji
- Ishikawa, Takayuki
- Tsurumi, Hisashi
- Takaori-Kondo, Akifumi
- Kiguchi, Toru
- Polprasert, Chantana
- Bennett, John M.
- Savona, Michael R.
- Belickova, Monika
- Ganster, Christina
- Palomo, Laura
- Sanz, Guillermo
- Elias, Harold K.
- Smith, Alexandra G.
- Werner, Yesenia
- Neuberg, Donna S.
- Stevenson, Kristen E.
- Menghrajani, Kamal
- Bolton, Kelly L.
- Fenaux, Pierre
- Pellagatti, Andrea
- Platzbecker, Uwe
- Heuser, Michael
- Valent, Peter
- Miyazaki, Yasushi
- Finelli, Carlo
- Voso, Maria Teresa
- Shih, Lee-Yung
- Fontenay, Michaela
- Jansen, Joop H.
- Cervera, José
- Atsuta, Yoshiko
- Ebert, Benjamin L.
- Bejar, Rafael
- Greenberg, Peter L.
- Cazzola, Mario
- Ogawa, Seishi
- Papaemmanuil, Elli
- Venue
- Nature Medicine
- Published
- 2020-08-03
- Volume
- 26
- Issue
- 10
- Pages
- 1549-1556
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC8381722
- OpenAlex
- W3046671820
- Cited by
- 648
- References
- 58
- Citations by year
- 2026: 73 · 2025: 91 · 2024: 106 · 2023: 136 · 2022: 130 · 2021: 87 · 2020: 22
- FWCI
- 59.16
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- doi.org
- Licence
- Locations
- Nature Medicine (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Amgen
- Pfizer
- Sanofi
- Alexion Pharmaceuticals
- Celgene (21267)
- Helsinn
- European Hematology Association
- Japan Agency for Medical Research and Development (JP18ck0106353, 19ck0106250h0003, JP19cm0106501)
- Taiho Pharmaceutical
- TG Therapeutics
- Astex Pharmaceuticals
- Sunesis
- Incyte
- Nippon Shinyaku
- Celltrion
- Geoffrey Beene Foundation
- Cancer Research UK (29685)
- Agence Nationale de la Recherche (ANR-18-IBHU-0003)
- Ministry of Education, Culture, Sports, Science and Technology (hp160219)
- Austrian Science Fund (#F4704-B20)
- Ministero dell’Istruzione, dell’Università e della Ricerca (21267)
- Astellas Pharma
- Associazione Italiana per la Ricerca sul Cancro (21267, 5×1000, 20125, 13042, project #21267, IG #20125)
- Genesis Pharma
- Otsuka Pharmaceutical
- Ono Pharmaceutical
- Blood Cancer UK (13042)
- Chugai Pharmaceutical
- Pharmacyclics
- Sanofi K.K.
- Japan Society for the Promotion of Science (19H03684, 13042, 18H02836, 26221308, hp160219, 19H05656, 15H05909)
- National Cancer Institute (P30CA008748, K12CA184746, P50CA254838)
- Daiichi Sankyo Europe
- Cilag
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- TP53 mutation, myelodysplastic syndrome, allelic state, monoallelic variants, biallelic variants, genome stability, leukemic transformation, acute myeloid leukemia, complex karyotype, prognosis, treatment response, wild-type p53
- MeSH terms
- Alleles, DNA Mutational Analysis, Female, Gene Frequency, Humans, Male, Mutation, Myelodysplastic Syndromes, Phenotype, Prognosis, Cohort Studies, Survival Analysis, Tumor Suppressor Protein p53, Treatment Outcome, Loss of Heterozygosity, Genomic Instability, DNA Copy Number Variations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
